Morgan Stanley Maintains Equal-Weight on TransMedics Gr, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong has maintained an Equal-Weight rating on TransMedics Group (TMDX) and increased the price target from $75 to $95.

February 28, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on TransMedics Group but raised the price target from $75 to $95.
The increase in price target by a reputable analyst like Cecilia Furlong at Morgan Stanley suggests a positive outlook on the stock's future performance. This adjustment reflects an expectation of higher future valuation, which could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100